PLANNING AND EVALUATION The LCCC internal and external advisory groups provided invaluable guidance in planning and evaluation of all the major initiatives and includes: ? The Senior Leadership Team, which is composed of the Director, Deputy Director and Associate Directors and meets weekly to evaluate progress in strategic LCCC initiatives. ? The Program Planning Committee, which meets monthly to evaluate progress of all important initiatives and includes institutional and Research Program Leaders, as well as the Senior Leadership Team. ? The Internal Advisory Board, comprised of institutional leaders including the Chancellor; Dean of the College of Arts and Sciences, Deans of the Schools of Medicine, Pharmacy, and Public Health and external advisors, and meets with the Director at least quarterly. ? The Scientific Advisory Board (SAB), which is comprised of expert external advisors, and which was expanded with the addition of two new members in 2018/19 to provide additional expertise in specific areas such as community outreach and engagement and clinical trials. There are now 14 members on the SAB with complementary expertise in basic, clinical, translational, and population sciences and administration. The SAB meets at least annually at the UNC LCCC. ? The Community Advisory Board (CAB), the 12 membered CAB meets quarterly with the Director and COE Leadership. The CAB is geographically, racially and ethnically representative of our catchment area (the state of North Carolina) and offers a variety of important perspectives and constituencies, including cancer survivors and caregivers, community and faith-based organizations, rural and urban areas, state and non-profit agencies, and under-represented minorities. These coordinated teams of advisors provide critical advice and guidance, both annually in the fall and ad-hoc as required, ensuring that LCCC most effectively set priorities and pursues objectives that promote basic, clinical, prevention and translational research at the Center. With careful planning and critical input from advisory groups, the Director initiated a new 5 year strategic planning process, reorganized operating committees, continued significant recruitment, launched new population-based studies, strengthened community outreach efforts, and expanded immunotherapy and GMP infrastructure.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089822
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Mayer, Deborah K; Landucci, Gina; Awoyinka, Lola et al. (2018) SurvivorCHESS to increase physical activity in colon cancer survivors: can we get them moving? J Cancer Surviv 12:82-94
Huo, Dezheng; Perou, Charles M; Olopade, Olufunmilayo I (2018) Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply. JAMA Oncol 4:883-884
Howe, Chanelle J; Robinson, Whitney R (2018) Survival-related Selection Bias in Studies of Racial Health Disparities: The Importance of the Target Population and Study Design. Epidemiology 29:521-524
Byrne, James D; Yeh, Jen Jen; DeSimone, Joseph M (2018) Use of iontophoresis for the treatment of cancer. J Control Release 284:144-151
Wilkin, Timothy J; Chen, Huichao; Cespedes, Michelle S et al. (2018) A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis 67:1339-1346
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Ubil, Eric; Caskey, Laura; Holtzhausen, Alisha et al. (2018) Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. J Clin Invest 128:2356-2369
Hamad, Ahmad; Iweala, Onyinye I; Henderson, Cory et al. (2018) Recurrent anaphylaxis during cardiac catheterization due to ethylene oxide. J Allergy Clin Immunol Pract 6:2148-2150
Ho, G-T; Aird, R E; Liu, B et al. (2018) MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation. Mucosal Immunol 11:120-130
Pearce, Oliver M T; Delaine-Smith, Robin M; Maniati, Eleni et al. (2018) Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. Cancer Discov 8:304-319

Showing the most recent 10 out of 1525 publications